Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PIPE-791 Dose A
PIPE-307 Dose A · 1 trial · 1 indication
Number of participants with TEAEs
| Arm | Type | Description |
|---|---|---|
| PIPE-307 Dose A | EXPERIMENTAL | - |
| PIPE-307 Dose B | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PIPE-307 Dose A | DRUG | Subjects will receive daily oral doses of PIPE-307 |
| PIPE-307 Dose B | DRUG | Subjects will receive daily oral doses of PIPE-307 |
| Placebo | DRUG | Subjects will receive daily oral matching dose of Placebo |
Inclusion Criteria: * Subject is fluent in English. * Male or female 18 to 50 years of age, inclusive, at the first Screening visit. * A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria. * Expanded Disability Status Scale (EDSS) and retinal ...
PIPE-791 Dose A is an investigational small molecule being studied for idiopathic pulmonary fibrosis (IPF) and relapsing remitting multiple sclerosis (RRMS). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
PIPE-791 Dose A targets the lysophosphatidic acid receptor 1 (LPAR1). By modulating this receptor, the drug is being evaluated for its potential effects in treating idiopathic pulmonary fibrosis and relapsing remitting multiple sclerosis.
PIPE-791 Dose A is being developed by Contineum Therapeutics, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol CTNM.
PIPE-791 Dose A is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Clinical trials are ongoing to evaluate its safety and efficacy in patients with idiopathic pulmonary fibrosis.
PIPE-791 Dose A is being studied in a Phase 2 trial (NCT07284459) for idiopathic pulmonary fibrosis, which is currently recruiting 324 participants across multiple countries. A separate Phase 2 trial (NCT06083753) for relapsing remitting multiple sclerosis has been completed.
PIPE-791 Dose A is a specific dose formulation of the investigational drug PIPE-791. The clinical trial NCT07284459 evaluates PIPE-791 in patients with idiopathic pulmonary fibrosis, and the completed trial NCT06083753 studied PIPE-307 in relapsing remitting multiple sclerosis.